heart-diseases-2017-keynote

4 / 6

Page 14
alliedacademies
Curr Trend Cardiol. 2017 | Volume 1 Issue 3
September 18-19, 2017 | Toronto, Canada
Annual Conference on
HEART DISEASES
Notes:
Antiplatelets are mainly used in the prevention and
management of atherothrombotic complications.
Current ACC/AHA/ESC guidelines suggest dual antiplatelet
therapy (combining aspirin & clopidogrel) for patients having
acute coronary syndromes or undergoing PCI. But in spite of
administration of dual antiplatelet therapy, some patients
develop recurrent cardiovascular ischemic events especially
stent thrombosis which is a serious clinical problem.
Clopidogrel is an effective inhibitor of platelet activation and
aggregation due to selective and irreversible blockade of the
P2Y2 receptors. The mechanism of clopidogrel resistance
remains incompletely defined but there are certain clinical,
cellular and genetic factors including polymorphisms
responsible for therapeutic failure. The prevalence of
clopidogrel nonresponse varies from 4% to 30% 24 hours
after administration. Currently there is no standardized
or widely accepted definition of clopidogrel resistance.
This presentation is focussed on the methods used to
identify patients with clopidogrel resistance, the underlying
mechanisms, metabolism, clinical significance and current
therapeutic strategies to overcome clopidogrel resistance.
Speaker Biography
Nirankar Singh Neki, MBBS, MD(Internal Medicine) is working as Professor and Head of
Medicine unit 2 at Govt. Medical College Amritsar, India. He has teaching experience
of 30 years as undergraduate teacher and 28 years as postgraduate teacher. He
has an entry in the Limca Book of Records of 2015 for being the recipient of four
Fellowships of the Royal College of Physicians (Edinbourgh, Glasgow, Ireland and
London). In total he has 38 fellowship awards with different institutes. He is receipient
of FACC(USA),FAHA(USA), FESC, FACP(USA),and holds name in cardiology .Dr. Neki
holds 13 different Oration Awards and has been a named author in 365 scientific
publications, including book chapters. He is also Editor in Chief, Senior Editor, Editor,
Section Editor, and Associate Editor of more than 13 national and international medical
journals. Dr. Neki has been a Visiting Professor at James Cook University Hospital in
Durham, UK and at the University of Manitoba’s Institute of Cardiovascular Sciences at
St. Boniface Hospital &Research Centre, Winnipeg, Canada.
e:
Nirankar Singh Neki
Government Medical College, India
Clopidogrel resistance-Current issues